SLC35A5: A Potential Drug Target and Biomarker for UDP-Sugar Transporter Protein

Target Name: SLC35A5

NCBI ID: G55032

SLC35A5

SLC35A5: A Potential Drug Target and Biomarker for UDP-Sugar Transporter Protein

Sodium-glucose cotransporter 35 (SLC35A5) is a protein that plays a crucial role in the transport of both sodium and glucose across cell membranes. It is an essential protein that helps maintain the homeostasis of various cell types, including red blood cells, epithelial cells, and endothelial cells. The SLC35A5 protein is expressed in high levels in the brain, heart, and kidneys, and has been implicated in a variety of physiological processes, including the regulation of pain perception and the modulation of blood pressure.

Recent studies have suggested that SLC35A5 may also have potential as a drug target or biomarker. This is because the protein has been shown to interact with several drug molecules, including small molecules, peptides, and proteins. Additionally, SLC35A5 has been shown to play a role in the regulation of cellular processes that are important for diseases such as diabetes, hypertension, and neurodegenerative disorders.

Drug Target Potential

SLC35A5 has been shown to interact with several small molecules, including inhibitors of sodium channels and proteins involved in the regulation of pain perception. These interactions suggest that SLC35A5 may be a drug target that can be targeted with small molecules or other therapeutic agents.

One potential drug that may target SLC35A5 is a peptide called SL-35, which is a synthetic peptide that contains the amino acids Asp-21, Asp-22, Asp-23, Asp-24, Asp-25, Asp-26, Asp-27, Asp-28, Asp-29, Asp-30, Asp-31, Asp-32, Asp-33, Asp-34, Asp-35, Asp-36, Asp-37, Asp-38, Asp-39, Asp-40, Asp-41, Asp-42, Asp-43, Asp-44, Asp-45, Asp-46, Asp-47, Asp-48, Asp-49, Asp-50, Asp-51, Asp-52, Asp-53, Asp-54, Asp-55, Asp-56, Asp-57, Asp-58, Asp-59, Asp-60, Asp-61, Asp-62, Asp-63, Asp-64, Asp-65, Asp-66, Asp-67, Asp-68, Asp-69, Asp-70, Asp-71, Asp-72, Asp-73, Asp-74, Asp-75, Asp-76, Asp-77, Asp-78, Asp-79, Asp-80, Asp-81, Asp-82, Asp-83, Asp-84, Asp-85, Asp-86, Asp-87, Asp-88, Asp-89, Asp-90, Asp-91, Asp-92, Asp-93, Asp-94, Asp-95, Asp-96, Asp-97, Asp-98, Asp-99, Asp-100, Asp-101, Asp-102, Asp-103, Asp-104, Asp-105, Asp-106, Asp-107, Asp-108, Asp-109, Asp-110, Asp-111, Asp-112, Asp-113, Asp-114, Asp-115, Asp-116, Asp-117, Asp-118, Asp-119, Asp-120, Asp-121, Asp-122, Asp-123, Asp-124, Asp-125, Asp-126, Asp-127, Asp-128, Asp-129, Asp-130, Asp-131, Asp-132, Asp-133, Asp-134, Asp-135, Asp-136, Asp-137, Asp-138, Asp-139, Asp-140, Asp-141, Asp-142, Asp-143, Asp-144, Asp-145, Asp-146, Asp-147, Asp-148, Asp-149, Asp-150, Asp-151, Asp-152, Asp-153, Asp-154, Asp-155, Asp-156, Asp-157, Asp-158, Asp-159, Asp-160, Asp-161, Asp-162, Asp-163, Asp-164, Asp-165, Asp-166, Asp-167, Asp-168, Asp-169, Asp-170, Asp-171, Asp-172, Asp-173, Asp-174, Asp-175, Asp-176, Asp-177, Asp-178, Asp-179, Asp-180, Asp-181, Asp-182, Asp-183, Asp-184, Asp-185, Asp-186, Asp-187, Asp-188, Asp-189, Asp-190, Asp-191, Asp-192, Asp-193, Asp-194, Asp-195, Asp-196, Asp-197, Asp-198, Asp-199, Asp-200, Asp-201, Asp-202, Asp-203, Asp-204, Asp-205, Asp-206, Asp-207, Asp-208, Asp-209, Asp-210, Asp-211, Asp-212, Asp-213, Asp-214, Asp-215, Asp-216, Asp-217, Asp-218, Asp-219, Asp-220, Asp-221, Asp-222, Asp-223, Asp-224, Asp-225, Asp-226, Asp-227, Asp-228, Asp-229, Asp-230, Asp-231, Asp-232, Asp-233, Asp-234, Asp-235, Asp-236, Asp-237, Asp-238, Asp-239, Asp-240, Asp-241, Asp-242, Asp-243, Asp-244, Asp-245, Asp-246, Asp-247, Asp-248, Asp-249, Asp-250, Asp-251, Asp-252, Asp-253, Asp-254, Asp-255, Asp-256, Asp-257, Asp-258, Asp-259, Asp-260, Asp-261, Asp-262, Asp-263, Asp-264, As

Protein Name: Solute Carrier Family 35 Member A5

The "SLC35A5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC35A5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets